With this funding, the company will advance research and development beyond the second pipeline, which has been prepared in parallel with domestic clinical trials in metastatic recurrent HER2-negative breast cancer, including triple-negative breast cancer, which are due to start shortly.

PRTIMES
Chushin Venture Capital Co.